使用 Cu-DOTA-曲妥珠单抗 PET 预测接受曲妥珠单抗-美坦新偶联物治疗转移性乳腺癌患者的反应和结局：一项初步研究。
Use of Cu-DOTA-Trastuzumab PET to Predict Response and Outcome of Patients Receiving Trastuzumab Emtansine for Metastatic Breast Cancer: A Pilot Study.
机构信息
Department of Medical Oncology and Experimental Therapeutics, City of Hope, Duarte, California;
Department of Medical Oncology and Experimental Therapeutics, City of Hope, Duarte, California.
出版信息
J Nucl Med. 2022 Aug;63(8):1145-1148. doi: 10.2967/jnumed.121.262940. Epub 2021 Dec 2.
Abstract
We hypothesized that functional imaging with Cu-DOTA-trastuzumab PET/CT would predict the response to the antibody-drug conjugate trastuzumab-emtansine (T-DM1). Ten women with metastatic human epidermal growth factor receptor 2-positive breast cancer underwent F-FDG PET/CT and Cu-DOTA-trastuzumab PET/CT on days 1 and 2 before treatment with T-DM1. T-DM1-responsive patients had higher uptake than nonresponsive patients. Day 1 minimum SUV (5.6 vs. 2.8, < 0.02), day 2 minimum SUV (8.1 vs. 3.2, < 0.01), and day 2 average SUV (8.5 vs. 5.4, < 0.05) for Cu-DOTA-trastuzumab all favored responding patients. Tumor-level response suggested threshold dependence on SUV Patients with a day 2 minimum SUV above versus below the threshold had a median time to treatment failure of 28 mo versus 2 mo ( < 0.02). Measurement of trastuzumab uptake in tumors via PET/CT is promising for identifying patients with metastatic breast cancer who will benefit from T-DM1.
摘要
我们假设使用 Cu-DOTA-曲妥珠单抗 PET/CT 的功能成像将预测对抗体药物偶联物曲妥珠单抗-美坦新（T-DM1）的反应。10 名患有转移性人表皮生长因子受体 2 阳性乳腺癌的女性在接受 T-DM1 治疗前的第 1 天和第 2 天分别进行了 F-FDG PET/CT 和 Cu-DOTA-曲妥珠单抗 PET/CT。T-DM1 有反应的患者比无反应的患者摄取更高。第 1 天最小 SUV（5.6 比 2.8， < 0.02），第 2 天最小 SUV（8.1 比 3.2， < 0.01），第 2 天平均 SUV（8.5 比 5.4， < 0.05）均有利于有反应的患者。肿瘤水平的反应提示 SUV 存在阈值依赖性。第 2 天 SUV 低于或高于阈值的患者中位无进展生存期分别为 28 个月和 2 个月（<0.02）。通过 PET/CT 测量肿瘤内曲妥珠单抗摄取对于识别将从 T-DM1 中受益的转移性乳腺癌患者具有前景。
相似文献
1
Use of Cu-DOTA-Trastuzumab PET to Predict Response and Outcome of Patients Receiving Trastuzumab Emtansine for Metastatic Breast Cancer: A Pilot Study.使用 Cu-DOTA-曲妥珠单抗 PET 预测接受曲妥珠单抗-美坦新偶联物治疗转移性乳腺癌患者的反应和结局：一项初步研究。
J Nucl Med. 2022 Aug;63(8):1145-1148. doi: 10.2967/jnumed.121.262940. Epub 2021 Dec 2.
2
Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.使用 (64)Cu-DOTA-曲妥珠单抗 PET 对人表皮生长因子受体 2 阳性转移性乳腺癌进行功能成像。
J Nucl Med. 2014 Jan;55(1):23-9. doi: 10.2967/jnumed.113.122630. Epub 2013 Dec 12.
3
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.分子成像作为一种工具，用于研究晚期HER2阳性乳腺癌的异质性，并预测接受曲妥珠单抗-恩杂鲁胺（T-DM1）治疗的患者预后：ZEPHIR试验。
Ann Oncol. 2016 Apr;27(4):619-24. doi: 10.1093/annonc/mdv577. Epub 2015 Nov 23.
4
Tumor Uptake of Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer.转移性乳腺癌患者中 Cu-DOTA-曲妥珠单抗的肿瘤摄取。
J Nucl Med. 2018 Jan;59(1):38-43. doi: 10.2967/jnumed.117.193888. Epub 2017 Jun 21.
5
Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population.比较曲妥珠单抗-美坦新偶联物在既往接受曲妥珠单抗和帕妥珠单抗联合治疗与仅接受曲妥珠单抗治疗的人表皮生长因子受体 2 阳性转移性乳腺癌日本患者中的疗效。
Breast Cancer. 2019 Jul;26(4):492-498. doi: 10.1007/s12282-019-00949-4. Epub 2019 Feb 8.
6
Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study.曲妥珠单抗联合阿替利珠单抗治疗早期或转移性乳腺癌对肿瘤免疫微环境的影响：来自 Ib 期研究的结果。
Clin Breast Cancer. 2021 Dec;21(6):539-551. doi: 10.1016/j.clbc.2021.04.011. Epub 2021 May 15.
7
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial.曲妥珠单抗、帕妥珠单抗和多西他赛新辅助治疗与曲妥珠单抗-美坦新偶联物治疗人表皮生长因子受体 2 阳性乳腺癌患者的Ⅱ期随机临床试验
JAMA Oncol. 2021 Sep 1;7(9):1360-1367. doi: 10.1001/jamaoncol.2021.1932.
8
64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer.64Cu-DOTA-曲妥珠单抗 PET 显像用于 HER2 阳性乳腺癌患者。
J Nucl Med. 2013 Nov;54(11):1869-75. doi: 10.2967/jnumed.112.118612. Epub 2013 Sep 12.
9
Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.ado曲妥珠单抗（T-DM1）：一种用于治疗HER2阳性转移性乳腺癌的新型抗体药物偶联物。
J Oncol Pharm Pract. 2015 Apr;21(2):132-42. doi: 10.1177/1078155214527144. Epub 2014 Mar 27.
10
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.曲妥珠单抗-美坦新偶联物用于治疗残留浸润性 HER2 阳性乳腺癌。
N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5.
引用本文的文献
1
MIB guides: [Zr]Zr-DFO-trastuzumab and [Cu]Cu-NOTA-Trastuzumab for Preclinical Cancer Imaging.MIB指南：用于临床前癌症成像的[锆]锆-DFO-曲妥珠单抗和[铜]铜-NOTA-曲妥珠单抗
Mol Imaging Biol. 2025 Jun 26. doi: 10.1007/s11307-025-02022-3.
2
The role of dual-tracer PET imaging with ER and HER2 in patients with metastatic breast cancer: a pilot study.双示踪剂PET成像联合雌激素受体（ER）和人表皮生长因子受体2（HER2）在转移性乳腺癌患者中的作用：一项初步研究。
Ann Nucl Med. 2025 Jun 26. doi: 10.1007/s12149-025-02071-2.
3
HER2 expression in different cell lines at different inoculation sites assessed by [Mn]Mn-DOTAGA(anhydride)-trastuzumab.通过[锰]锰-多他加（酸酐）-曲妥珠单抗评估不同接种部位不同细胞系中的HER2表达。
Pathol Oncol Res. 2025 Apr 29;31:1611999. doi: 10.3389/pore.2025.1611999. eCollection 2025.
4
Novel treatment approaches utilizing antibody-drug conjugates in breast cancer.利用抗体药物偶联物治疗乳腺癌的新方法。
NPJ Breast Cancer. 2025 May 13;11(1):42. doi: 10.1038/s41523-025-00743-w.
5
Radiocopper in Radiopharmacy and Medical Use: Current Status and Perspective.放射性药物学与医学应用中的放射性铜：现状与展望
J Med Chem. 2025 Feb 13;68(3):2356-2376. doi: 10.1021/acs.jmedchem.4c02885. Epub 2025 Feb 2.
6
Novel Molecular Classification of Breast Cancer with PET Imaging.基于PET成像的乳腺癌新型分子分类
Medicina (Kaunas). 2024 Dec 21;60(12):2099. doi: 10.3390/medicina60122099.
7
[Cu]Cu-NOTA-Trastuzumab and [Zr]Zr-DFO-Trastuzumab in Xenografts with Varied HER2 Expression.具有不同HER2表达的异种移植瘤中的[铜]铜- NOTA -曲妥珠单抗和[锆]锆- DFO -曲妥珠单抗
Mol Pharm. 2024 Dec 2;21(12):6311-6322. doi: 10.1021/acs.molpharmaceut.4c00777. Epub 2024 Oct 29.
8
The Role of Molecular Imaging in Precision Oncology.分子成像在精准肿瘤学中的作用。
J Nucl Med. 2024 Nov 1;65(11):1818. doi: 10.2967/jnumed.124.268036.
9
Radiotracer Innovations in Breast Cancer Imaging: A Review of Recent Progress.乳腺癌成像中的放射性示踪剂创新：近期进展综述
Diagnostics (Basel). 2024 Sep 3;14(17):1943. doi: 10.3390/diagnostics14171943.
10
Development of Mn Labeled Trastuzumab for Extended Time Point PET Imaging of HER2.Mn 标记曲妥珠单抗用于 HER2 的延长时间点 PET 成像的开发。
Mol Imaging Biol. 2024 Oct;26(5):858-868. doi: 10.1007/s11307-024-01948-4. Epub 2024 Aug 27.
本文引用的文献
1
Functional Imaging of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers and a Note about NOTA.人表皮生长因子受体2阳性乳腺癌的功能成像及关于氮杂环辛四烯（NOTA）的说明
J Nucl Med. 2019 Jan;60(1):23-25. doi: 10.2967/jnumed.118.220905. Epub 2018 Dec 20.
2
Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update.晚期人表皮生长因子受体 2 阳性乳腺癌患者的系统治疗：ASCO 临床实践指南更新。
J Clin Oncol. 2018 Sep 10;36(26):2736-2740. doi: 10.1200/JCO.2018.79.2697. Epub 2018 Jun 25.
3
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.人表皮生长因子受体 2 检测在乳腺癌中的应用：美国临床肿瘤学会/美国病理学家学院临床实践指南的重点更新。
J Clin Oncol. 2018 Jul 10;36(20):2105-2122. doi: 10.1200/JCO.2018.77.8738. Epub 2018 May 30.
4
Tumor Uptake of Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer.转移性乳腺癌患者中 Cu-DOTA-曲妥珠单抗的肿瘤摄取。
J Nucl Med. 2018 Jan;59(1):38-43. doi: 10.2967/jnumed.117.193888. Epub 2017 Jun 21.
5
Pharmacokinetics, Biodistribution, and Radiation Dosimetry for Zr-Trastuzumab in Patients with Esophagogastric Cancer.Zr-曲妥珠单抗在食管胃结合部癌患者中的药代动力学、生物分布和辐射剂量学。
J Nucl Med. 2018 Jan;59(1):161-166. doi: 10.2967/jnumed.117.194555. Epub 2017 Jun 21.
6
Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT.使用89Zr-曲妥珠单抗PET/CT检测HER2阴性原发性乳腺癌患者中的HER2阳性转移灶。
J Nucl Med. 2016 Oct;57(10):1523-1528. doi: 10.2967/jnumed.115.172031. Epub 2016 May 5.
7
[Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer.[锆]曲妥珠单抗：HER2阳性乳腺癌女性患者的放射剂量测定、安全性及最佳成像参数评估
Mol Imaging Biol. 2016 Dec;18(6):952-959. doi: 10.1007/s11307-016-0951-z.
8
HER2 imaging in the ZEPHIR study.ZEPHIR研究中的HER2成像。
Ann Oncol. 2016 Apr;27(4):555-7. doi: 10.1093/annonc/mdw033. Epub 2016 Jan 22.
9
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.分子成像作为一种工具，用于研究晚期HER2阳性乳腺癌的异质性，并预测接受曲妥珠单抗-恩杂鲁胺（T-DM1）治疗的患者预后：ZEPHIR试验。
Ann Oncol. 2016 Apr;27(4):619-24. doi: 10.1093/annonc/mdv577. Epub 2015 Nov 23.
10
Targeting HER2 for the treatment of breast cancer.针对乳腺癌的 HER2 靶向治疗。
Annu Rev Med. 2015;66:111-28. doi: 10.1146/annurev-med-042513-015127.
Zotero 插件